title: Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs.
abstract: OBJECTIVE
  To investigate the effect of cilostazol, in kidney and skeletal muscle of rats submitted to acute ischemia and reperfusion.
  
  
  METHODS
  Fourty three animals were randomized and divided into two groups. Group I received a solution of cilostazol (10 mg/Kg) and group II received saline solution 0.9% (SS) by orogastric tube after ligature of the abdominal aorta. After four hours of ischemia the animals were divided into four subgroups: group IA (Cilostazol): two hours of reperfusion. Group IIA (SS): two hours of reperfusion. Group IB (Cilostazol): six hours of reperfusion. Group IIB (SS) six hours of reperfusion. After reperfusion, a left nephrectomy was performed and removal of the muscles of the hind limb. The histological parameters were studied. In kidney cylinders of myoglobin, vacuolar degeneration and acute tubular necrosis. In muscle interstitial edema, inflammatory infiltrate, hypereosinophilia fiber, cariopicnose and necrosis. Apoptosis was assessed by immunohistochemistry for cleaved caspase-3 and TUNEL.
  
  
  RESULTS
  There was no statistically significant difference between groups.
  
  
  CONCLUSIONS
  Cilostazol had no protective effect on the kidney and the skeletal striated muscle in rats submitted to acute ischemia and reperfusion in this model.
authors.affiliation: Department of Surgery, Vascular Surgery Division, UMC, Mogi das Cruzes, SP, Brazil. femareis@yahoo.com.br
authors.forename: Antonio Augusto
authors.initials: AA
authors.lastname: Moreira Neto
authors.forename: Sylvio Sebastião de
authors.initials: SS
authors.lastname: Souza Júnior
authors.forename: Vera Luíza
authors.initials: VL
authors.lastname: Capelozzi
authors.forename: Edwin Roger
authors.initials: ER
authors.lastname: Parra-Cuentas
authors.forename: Aurelino Fernandes
authors.initials: AF
authors.lastname: Schmidt Júnior
authors.forename: Acácio
authors.initials: A
authors.lastname: Francisco Neto
authors.forename: Olavo Ribeiro
authors.initials: OR
authors.lastname: Rodrigues
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000032:analysis; D000077407:Cilostazol; D004195:Disease Models, Animal; D006614:Hindlimb / Q000098:blood supply* / Q000187:drug effects*; D020287:In Situ Nick-End Labeling; D007511:Ischemia / Q000188:drug therapy*; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D008297:Male; D018482:Muscle, Skeletal / Q000098:blood supply / Q000187:drug effects*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000517:prevention & control; D015203:Reproducibility of Results; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D013777:Tetrazoles; D014665:Vasodilator Agents; D053148:Caspase 3; D000077407:Cilostazol